We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Driven Blood Test to Revolutionize Diagnosis of Long COVID in Children

By LabMedica International staff writers
Posted on 29 Jan 2025

Long COVID affects about 0. More...

5% of pediatric patients exposed to SARS-CoV-2. Also known as post-COVID or post-acute sequelae of SARS-CoV-2, this condition is characterized by persistent symptoms that appear after the viral infection and last for at least 8-12 weeks, significantly impacting daily life. Long COVID has been observed across all age groups, with children over the age of 10 being particularly affected in terms of severity. While proteomic studies have highlighted a pro-inflammatory signature and thrombo-inflammation in adults with long COVID, similar findings had not been documented in the pediatric population. Now, a new method can accurately diagnose long COVID in children using a blood sample and artificial intelligence (AI).

In a study led by researchers at Università Cattolica del Sacro Cuore (UCSC, Milan, Italy) and associated institutions, an AI tool was found to effectively detect the molecular signature of long COVID in plasma samples from pediatric patients, with an accuracy rate of 93%. For their research, the team performed a detailed protein analysis on blood plasma from children under 19 years of age, comparing those with long COVID to control groups including children with acute COVID-19, MIS-C, and healthy controls. Children were classified as having long COVID if they experienced persistent symptoms for at least 8 weeks after the initial infection, which negatively impacted their daily activities and could not be attributed to other causes. The study included 112 children, with 34 meeting the clinical criteria for long COVID, 32 with acute SARS-CoV-2 infection, 27 with MIS-C, and 19 healthy controls.

The study, published in the journal Pediatric Research, showed that children with long COVID showed higher expression of a specific set of pro-inflammatory and pro-angiogenic chemokines (CXCL11, CXCL1, CXCL5, CXCL6, CXCL8, TNFSF11, OSM, STAMBP1a) compared to controls. Using a machine learning model based on this proteomic profile, researchers identified long COVID with an accuracy of 93%, a specificity of 86%, and a sensitivity of 97%. The findings indicate that pediatric long COVID is characterized by an increased blood protein signature associated with ongoing general and endothelial inflammation, similar to what has been observed in adults. This study is the first to document the pro-inflammatory profile in children with long COVID, and the results may contribute to the development of future diagnostic tests.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.